Antithrombotic Management and Long-Term Outcomes of Patients with Atrial Fibrillation. Insights from CRAFT Trial.
Paweł BalsamPiotr LodzińskiMonika GawalkoLeszek KrajAndrzej ŚliwczyńskiCezary MaciejewskiBartosz KrzowskiKrzysztof OzierańskiKrzysztof OzierańskiMarcin GrabowskiJanusz BednarskiGrzegorz OpolskiPublished in: Journal of clinical medicine (2021)
Despite no difference in the thromboembolic event rate, treatment with VKA and rivaroxaban was associated with a significant increase in the risk of hemorrhagic events.